disitamab vedotin
Sponsor PFE · listed as PFE
READOUT
Phase 3
Confidence: medium
Source: clinicaltrials
disitamab vedotin is a clinical-stage drug asset sponsored by PFE, listed as PFE. CSA tracks 2 forward catalysts for it — the nearest is a readout expected Dec 31, 2026 (day precision, medium confidence), tied to trial NCT05302284. The asset is in Phase 3 and currently recruiting, studied in Urothelial Carcinoma. It appears across 5 tracked trials in the CSA sample.
Next catalyst
Event typeREADOUT
Expected date2026-12-31
As disclosedDec 31, 2026
Date precisionday
Confidencemedium
Trial & sponsor
Trial (NCT)NCT05302284
PhasePHASE3
StatusRECRUITING
Lead sponsorRemeGen Co., Ltd.
Listed asPFE
Condition(s)Urothelial Carcinoma; HER2-expressing
All tracked catalysts for disitamab vedotin
| Date | Event | Confidence | Trial |
|---|---|---|---|
| 2026-12-31 | READOUT | medium | NCT05302284 |
| 2027-01-29 | READOUT | medium | NCT05911295 |
!
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.
Get the full dataset — $499 → More PFE catalysts